Q/C Technologies, Inc. (QCLS) stock
QCLSNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.33+0.01 (+4.05%)
Close on Nov 17, 2026Market cap $2.74MP/E –Yield –
Q/C Technologies ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Q/C Technologies's ebitda for the twelve months ending Dec 31, 2020 was -$9.46M. For fiscal 2020 it was -$9.46M. The highest annual figure on record is -$1.46M in fiscal 2013.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | -$9.46M | – |
| FY2019 | Dec 31, 2019 | -$3.40M | – |
| FY2018 | Dec 31, 2018 | -$9.83M | – |
| FY2017 | Dec 31, 2017 | -$6.36M | – |
| FY2016 | Dec 31, 2016 | -$3.04M | – |
| FY2015 | Dec 31, 2015 | -$9.38M | – |
| FY2014 | Dec 31, 2014 | -$2.85M | – |
| FY2013 | Dec 31, 2013 | -$1.46M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2020 | Dec 31, 2020 | -$4.17M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.24M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.08M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.53M | – |
| Q4 FY2019 | Dec 31, 2019 | -$671.13K | – |
| Q3 FY2019 | Sep 30, 2019 | -$836.22K | – |
| Q2 FY2019 | Jun 30, 2019 | -$802.17K | – |
| Q1 FY2019 | Mar 31, 2019 | -$924.57K | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.87M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.06M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.06M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.84M | -548.8% |
| Q2 FY2017 | Jun 30, 2017 | -$760.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.30M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.03M | – |
| Q3 FY2016 | Sep 30, 2016 | $409.30K | – |
| Q2 FY2016 | Jun 30, 2016 | -$957.38K | – |
| Q1 FY2016 | Mar 31, 2016 | -$1.46M | – |
See a number that looks wrong?